Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Añadir filtros








Intervalo de año
1.
Chinese Journal of Rehabilitation Theory and Practice ; (12): 1016-1017, 2005.
Artículo en Chino | WPRIM | ID: wpr-979873

RESUMEN

@# 目的探讨脊髓损伤患者尿路感染常见细(真)菌及其对不同抗生素的敏感性和耐药情况。方法取脊髓损伤患者中段尿做尿培养及药敏试验,共计586例次。结果共培养出细(真)菌586株,其中革兰氏阴性杆菌475株(81.1%)、革兰氏阳性球菌83株(14.1%)、真菌28株(4.8%);产ESBL大肠埃希氏菌12株(2.05%)、产ESBL肺炎克雷伯氏菌5株(0.85%)。结论大肠埃希氏菌是导致本组患者尿路感染的最主要细菌,且细菌耐药现象较为严重,应引起临床医生高度重视。

2.
Chinese Journal of Rehabilitation Theory and Practice ; (12): 297-298, 2005.
Artículo en Chino | WPRIM | ID: wpr-978095

RESUMEN

@#ObjectiveTo investigate the resistance character and trend of bacteria strains producing extend spectrum β-lactamase (ESBLs) in clinic.MethodsThe ESBLs-producting K. pneumoniae and E.coli producing ESBLs isolated from Apr 2001 to Mar 2004 in our hospital were screened and confirmed according to NCCLs method.ResultsK. pneumoniae and E.coli with the ESBLs phenotype were increased in recent 3 years with the resistance rate and Gm(MIC) also higher than that not producing ESBLs.ConclusionThe dection of bacteria strains producing ESBLs will be enhanced in order to provide reasonable treatment information.

3.
Chinese Journal of Rehabilitation Theory and Practice ; (12): 28-31, 1995.
Artículo en Chino | WPRIM | ID: wpr-998369

RESUMEN

@#Wistar male rats were divided into two grorps, The experimental group was madethe paraplegia model. BOth groups were received cefazolinum 250 mg through single-dosed intra-venous injection. The concentration was measured by HPLC. The result implied that a).the concentra-tion of cefazolinum in paraplegic group was higher than that in control group either the distributingphase or the eliminating phase(p<0. 001);b). the pharmacokinetic parameters showed that the apparent vlumeof distribution:(v1,v2)was decreased and the elimination. half-life(t1/2β)was more length-y in paraplegia group. So that the drug concentration increased. The conclusion is that the dosege on thepatients with paraplegia should be clinically monitored,especilly following hepatic and renal disfunctionand with the drugs with narrowed safety range.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA